Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
Summary
The investigators hypothesize that, among non-hypertensive overweight and obese individuals, treatment of vitamin D deficiency and lowering uric acid concentrations (by either xanthine oxidase inhibition or increased renal excretion) will attenuate renin angiotensin system (RAS) activation, improve endothelial function, and lower blood pressure.
Timeline
- Start
- 2011-03
- Primary completion
- 2015-05
- Completion
- 2015-06
Outcome
Missed primary endpoint
registry analysis (superiority test); Vitamin D vs Placebo- Vitamin D; p = 0.72; Repeated Measures Analysis NCT01320722 ↗
registry analysis (superiority test); Vitamin D vs Placebo- Vitamin D; p = 0.77; t-test, 2 sided NCT01320722 ↗
registry analysis (superiority test); Vitamin D vs Placebo- Vitamin D; p = 0.57; t-test, 2 sided NCT01320722 ↗
registry Probenecid vs Placebo- Uric Acid; p = 0.8; Repeated Measures Analysis NCT01320722 ↗
registry Allopurinol vs Placebo- Uric Acid; p = 0.6; Repeated Measures Analysis NCT01320722 ↗
registry Probenecid vs Placebo- Uric Acid; p = 0.6; Repeated Measures Analysis NCT01320722 ↗
registry Allopurinol vs Placebo- Uric Acid; p = 0.7; Repeated Measures Analysis NCT01320722 ↗
registry Probenecid vs Placebo- Uric Acid; p = 0.3; Repeated Measures Analysis NCT01320722 ↗
registry Allopurinol vs Placebo- Uric Acid; p = 0.1; Repeated Measures Analysis NCT01320722 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Allopurinol | Small molecule | 300 mg | — |
| Subject | Allopurinol | Small molecule | 600 mg | — |
| Subject | Ergocalciferol | Small molecule | 50000 iu | — |
| Subject | Probenecid | Small molecule | 500 mg | — |
| Subject | Probenecid | Small molecule | 1000 mg | — |